Bio Medica Laboratories SME IPO
Bio Medica Laboratories IPO — date, price band, GMP & allotment 2026
Bio Medica Laboratories is a pharmaceutical company established in 2015 and based in Indore, Madhya Pradesh. The company is engaged in manufacturing parenteral formulations such as liquid injectables and dry powder injections for both human and veterinary healthcare segments. It operates mainly on a B2B contract manufacturing model, supplying ethical drugs, generic medicines and OTC products to pharmaceutical companies across multiple Indian states. The company also has GMP and GLP certified manufacturing facilities with a growing presence in domestic and export markets.
Stock price
Bio Medica Laboratories is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 13 September.
- Open 21 May 2026
- Close 25 May 2026
- Allotment 26 May 2026
- Refund/credit 27 May 2026
- Listing 29 May 2026
Issue summary
The terms of the offer, as filed.
| IPO Dates | 21 to 25 May, 2026 |
|---|---|
| Price Band | ₹132 – ₹139 |
| Face Value | ₹10 |
| Lot Size | 1000 Shares |
| Issue Size | ₹52 Cr |
| Sale Type | Fresh capital cum OFS |
| Listing On | NSE SME |
| Registrar | Skyline Financial Services Private Limited |
| Min Investment | ₹ 2,78,000 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 1000 shares at the ₹139 cut-off. The SME retail application is a fixed 2 lots; HNI starts at 3.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 2 | 2,000 | ₹2,78,000 |
| Retail (max) | 2 | 2,000 | ₹2,78,000 |
| HNI (min) | 3 | 3,000 | ₹4,17,000 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 5
- 01Experienced promoters and management team with pharma industry knowledge.
- 02Diversified portfolio of injectable pharmaceutical products for human and veterinary use.
- 03Strong quality assurance systems supported by GMP-certified manufacturing facilities.
- 04Established relationships with clients across multiple Indian states and healthcare markets.
- 05Significant improvement in revenue, EBITDA margins, and profitability during recent financial years.
Risks · 5
- 01High dependence on key customers may impact revenue if orders decline.
- 02Any quality control failure could damage reputation and invite legal liabilities.
- 03Failure to adopt new pharmaceutical technologies may affect future competitiveness.
- 04Negative cash flow risks may create pressure on expansion and working capital needs.
- 05The company operates from premises that are not fully owned, creating operational dependency risks.
Three years of numbers
All figures in ₹ crore, as reported in the Bio Medica Laboratories offer document.
| Metric | 30 Nov 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 65.17 | 39.12 | 19.53 | 17.57 |
| Total Income | 28.63 | 38.33 | 15.34 | 16.25 |
| Profit After Tax | 8.66 | 9.79 | 2.50 | 0.33 |
| EBITDA | 13.45 | 15.21 | 5.63 | 1.70 |
| NET Worth | 17.12 | 14.73 | 4.94 | 2.44 |
| Reserves and Surplus | 7.94 | 5.55 | 4.84 | 2.34 |
| Total Borrowing | 38.17 | 15.01 | 10.49 | 9.61 |
See how this IPO compares — view listing performance of all SME IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Bio Medica Laboratories RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.
Bio Medica Laboratories IPO Valuation
How the issue prices the company before and after the fresh shares are created.
| Valuation Metric | Post-Issue |
|---|---|
| EPS (₹) | ₹10.33 |
| P/E Ratio (x) | 13.45 |
| Market Cap at Offer Price (₹ Cr) | ₹116.53 |
Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹139 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.
Where the money goes
₹47.19 Cr of the issue is earmarked to named objects.
About the company
The company operates on a business model centred around the development, production, and distribution of pharmaceutical formulations and healthcare solutions across multiple therapeutic segments. Its product offerings include tablets, capsules, syrups, injections, and other medical formulations supplied through distributors and healthcare networks. The business is promoted by experienced industry professionals who focus on expanding market reach, improving manufacturing capabilities, and strengthening the company’s position in the domestic pharmaceutical industry.
Interested in this IPO? Check the live subscription status or browse all upcoming SME IPOs.
+91 7314102751
The bankers & the filings
Who is running the book, and the documents this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
Narnolia Financial Services Ltd
1 issue handled1 of their issues has listed so far, and 1 opened above the issue price (average +6.9%). That is too small a sample to read as a hit rate.
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Bio Medica Laboratories?
The current Grey Market Premium is ₹2, or 1% over the issue price.
What is the Bio Medica Laboratories IPO price band?
₹132 to ₹139, on a face value of ₹10.
When is the allotment?
The basis of allotment is 26 May 2026, with listing on 29 May 2026.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — Skyline Financial Services Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every SME and Mainboard issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
